Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection

Franco Locatelli, Alice Bertaina, Valentina Bertaina, Pietro Merli

Research output: Contribution to journalReview articlepeer-review


Introduction: Cytomegalovirus (CMV) still causes significant morbidity and mortality in patients given allogeneic hematopoietic stem cell transplantation (HSCT). Despite effective pharmacotherapy, potentially life-threatening CMV disease occurs nowadays in up to 10% of HSCT recipients; moreover, routinely used anti-CMV agents have been shown to be associated with morbidity. Areas covered: This review examines different issues related to diagnosis and management of CMV infection in HSCT recipients, paying particular attention to the monitoring of CMV-specific immune recovery, approaches of adoptive cell therapy and new antiviral drugs. Expert commentary: Despite advances in diagnostic tests and treatment, there is still room for refining management of CMV in HSCT recipients. Immunological monitoring should be associated in the future to virological monitoring. The safety profile and efficacy of new anti-CMV agents should be compared with that of standard-of-care drugs. Donor-derived, pathogen-specific T cells adoptively transferred after transplantation could contribute to reduce the impact of CMV infection on patient’s outcome.

Original languageEnglish
Pages (from-to)1093-1105
Number of pages13
JournalExpert Review of Hematology
Issue number11
Publication statusPublished - Nov 1 2016


  • adoptive T-cell therapy
  • anti-viral drugs
  • CMV infection
  • CMV vaccines
  • generation of CMV-specific T cells
  • immune monitoring
  • monitoring of CMV viral load

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection'. Together they form a unique fingerprint.

Cite this